We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This retrospective study examined the frequency of severe COVID-19 infections (hospitalization or death) in psoriasis patients receiving systemic and biologic therapy, including methotrexate, cyclosporine, acitretin, apremilast, etanercept, adalimumab, infliximab, certolizumab pegol, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and a combination of methotrexate and biologic therapy. Overall, 0.35% (5 of 1418) of patients had a severe COVID-19 infection requiring hospitalization, 60% of whom had other risk factors for severe infection. No deaths were reported. For those in the treatment-initiation period (first 4 months of therapy), there was no significant difference in the number of severe cases of COVID-19 (1 of 230 patients) versus those in the maintenance period (4 of 1188 patients; P = .58; OR, 1.29).
Only 0.35% of psoriasis patients on systemic and biologic therapy in this study were hospitalized for severe COVID-19 infection; none died. Hospitalization rates were similar between the initiation and maintenance periods. Although we are in the beginning stages of developing guidelines in the context of the COVID-19 pandemic, it is reasonable to initiate systemic and biologic therapy for severe psoriasis patients on a case-by-case basis.
– InYoung Kim, MD, PhD
This abstract is available on the publisher's site.
Some systemic and biologic psoriasis treatments [SBT] have been associated with an increased risk of infection.1 To date, more and more data regarding the risk of COVID-19 infection in patients receiving SBT become available.2-5
Journal of the European Academy of Dermatology and Venereology: JEADV
Systemic or Biologic Treatment in Psoriasis Patients Does Not Increase the Risk of a Severe Form of COVID‐19
J Eur Acad Dermatol Venereol 2020 Jun 21;[EPub Ahead of Print], AC Fougerousse, M Perrussel, PA Bécherel, E Begon, V Pallure, I Zaraa, G Chaby, J Parier, M Kemula, L Mery-Bossard, C Poreaux, C Taieb, F Maccari, Z Reguiai, the GEM Resopso